|
ES2582603T5
(es)
*
|
2008-10-01 |
2022-12-02 |
Amgen Res Munich Gmbh |
Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular
|
|
BR112014006376B1
(pt)
*
|
2011-09-19 |
2021-07-27 |
Axon Neuroscience Se |
Anticorpo isolado que se liga a um ou mais epítopos tau, ácido nucleico, vetor, composição farmacêutica, artigo de fabricação, dispositivo médico, método in vitro para diagnosticar ou triar um indivíduo quanto à presença de doença de alzheimer ou de uma tauopatia relacionada e usos do referido anticorpo
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CN113527469A
(zh)
|
2012-02-09 |
2021-10-22 |
中外制药株式会社 |
抗体的Fc区变异体
|
|
JP6324974B2
(ja)
*
|
2012-10-12 |
2018-05-23 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ |
タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬
|
|
CA2902026C
(en)
|
2013-03-13 |
2023-08-29 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
ES2778498T3
(es)
*
|
2013-12-20 |
2020-08-10 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
MX2016008098A
(es)
*
|
2013-12-20 |
2017-01-11 |
Hoffmann La Roche |
Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
|
|
KR102489452B1
(ko)
*
|
2014-02-02 |
2023-01-16 |
메디뮨 리미티드 |
Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질
|
|
CN108064248B
(zh)
*
|
2014-09-30 |
2022-03-15 |
生物控股有限公司 |
人源抗二肽重复(dpr)抗体
|
|
HRP20211273T1
(hr)
|
2014-11-26 |
2021-11-12 |
Xencor, Inc. |
Heterodimerna protutijela koja vežu cd3 i cd20
|
|
PL3303386T3
(pl)
|
2015-06-05 |
2025-03-03 |
Genentech, Inc. |
Przeciwciała anty-tau i sposoby zastosowania
|
|
TWI769982B
(zh)
*
|
2015-06-24 |
2022-07-11 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之抗人類運鐵蛋白受體抗體
|
|
EP3744732B1
(en)
|
2015-06-24 |
2025-09-10 |
F. Hoffmann-La Roche AG |
Humanized anti-tau(ps422) antibodies and methods of use
|
|
JP6914193B2
(ja)
|
2015-06-24 |
2021-08-04 |
Ｊｃｒファーマ株式会社 |
Ｂｄｎｆを含む融合蛋白質
|
|
WO2017005734A1
(en)
|
2015-07-06 |
2017-01-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
AU2016289753C1
(en)
*
|
2015-07-06 |
2021-08-05 |
UCB Biopharma SRL |
Tau-binding antibodies
|
|
EP3334761B1
(en)
*
|
2015-08-13 |
2023-07-19 |
New York University |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
WO2017176835A2
(en)
*
|
2016-04-06 |
2017-10-12 |
Imago Pharmaceuticals, Inc. |
Therapeutic antibodies for treatment of neurodegeneration
|
|
US10752679B2
(en)
|
2016-05-02 |
2020-08-25 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
EP3452508A1
(en)
|
2016-05-02 |
2019-03-13 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
PE20190208A1
(es)
|
2016-05-02 |
2019-02-07 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
WO2018017370A1
(en)
*
|
2016-07-20 |
2018-01-25 |
Anahit Ghochikyan |
Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
|
US10870709B2
(en)
*
|
2016-07-22 |
2020-12-22 |
New York University |
Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
|
|
TWI787219B
(zh)
|
2016-12-07 |
2022-12-21 |
美商建南德克公司 |
抗-ｔａｕ抗體及使用方法
|
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
EP3559044A4
(en)
*
|
2016-12-23 |
2020-12-02 |
REMD Biotherapeutics, Inc. |
IMMUNOTHERAPY USING ANTIBODIES THAT BINDING PROGRAMMED CELL DEATH 1 (PD-1)
|
|
EP3561058B1
(en)
|
2016-12-26 |
2025-07-23 |
JCR Pharmaceuticals Co., Ltd. |
Fusion protein including bdnf
|
|
NZ752703A
(en)
*
|
2016-12-26 |
2022-09-30 |
Japan Chem Res |
Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
|
|
EA039807B1
(ru)
*
|
2017-01-06 |
2022-03-16 |
ЭйБиЭл БИО ИНК. |
Антитело к -синуклеину и его применение
|
|
MX2019008827A
(es)
|
2017-01-30 |
2019-09-26 |
Alexion Pharma Inc |
Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
|
|
AU2018217720A1
(en)
*
|
2017-02-10 |
2019-09-05 |
The Trustees Of The University Of Pennsylvania |
Anti-factor D antibodies and uses thereof
|
|
MX2019010574A
(es)
*
|
2017-03-06 |
2020-01-15 |
Univ Pennsylvania |
Anticuerpos anti-c5 y su uso.
|
|
MX2019011252A
(es)
*
|
2017-03-23 |
2020-01-23 |
Univ Pennsylvania |
Anticuerpos anti-c5a y usos de los mismos.
|
|
WO2018178076A1
(en)
*
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110691793A
(zh)
*
|
2017-04-26 |
2020-01-14 |
田边三菱制药株式会社 |
黏结蛋白聚糖-1（cd138）结合剂及其用
|
|
MX2019013045A
(es)
|
2017-05-02 |
2020-02-12 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
WO2018218352A1
(en)
*
|
2017-05-30 |
2018-12-06 |
The University Of British Columbia |
Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
|
|
EP3431496A1
(en)
*
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
US12227567B2
(en)
|
2017-07-25 |
2025-02-18 |
Truebinding, Inc. |
Treating cancer by blocking the interaction of TIM-3 and its ligand
|
|
BR112020001970A2
(pt)
*
|
2017-08-02 |
2020-08-04 |
Stressmarq Biosciences Inc. |
anticorpo que se liga à alfa-sinucleína ativa
|
|
US11332527B2
(en)
*
|
2017-10-12 |
2022-05-17 |
Keio University |
Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof
|
|
JP2021504492A
(ja)
*
|
2017-11-29 |
2021-02-15 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム |
癌治療のための組成物および方法
|
|
EP3720880A1
(en)
*
|
2017-12-05 |
2020-10-14 |
Mabion SA |
Combination therapy of multiple sclerosis comprising a cd20 ligand
|
|
EP3724232B1
(en)
|
2017-12-14 |
2024-12-04 |
The University of Ottawa |
Exosome packaging and targeted autophagy
|
|
WO2019118906A2
(en)
*
|
2017-12-14 |
2019-06-20 |
University Of Florida Research Foundation |
Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
|
|
EP3725806A4
(en)
|
2017-12-14 |
2022-03-30 |
ABL Bio Inc. |
BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
|
|
CN118271444A
(zh)
|
2017-12-19 |
2024-07-02 |
瑟罗泽恩奥普瑞汀公司 |
Wnt替代分子和其用途
|
|
US11746150B2
(en)
*
|
2017-12-19 |
2023-09-05 |
Surrozen Operating, Inc. |
Anti-LRP5/6 antibodies and methods of use
|
|
US11440957B2
(en)
*
|
2017-12-29 |
2022-09-13 |
Alector Llc |
Anti-TMEM106B antibodies and methods of use thereof
|
|
CN111886247A
(zh)
*
|
2018-01-05 |
2020-11-03 |
Ac免疫有限公司 |
错折叠tdp-43结合分子
|
|
SG11202006770PA
(en)
*
|
2018-01-29 |
2020-08-28 |
Univ California |
Therapies and methods to treat tlr2-mediated diseases and disorders
|
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
|
CN112204050B
(zh)
|
2018-01-31 |
2025-03-14 |
艾莱克特有限责任公司 |
抗ms4a6a抗体及其使用方法
|
|
WO2019152895A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Memorial Sloan Kettering Cancer Center |
Antibodies to galectin-3 and methods of use thereof
|
|
WO2019161384A1
(en)
*
|
2018-02-19 |
2019-08-22 |
New York University |
Tau single domain antibodies
|
|
US12492254B2
(en)
|
2018-02-23 |
2025-12-09 |
H. Lee Moffitt Cancer Center and Research Intitute. Inc. |
CD83-binding chimeric antigen receptors
|
|
KR20200134253A
(ko)
*
|
2018-03-20 |
2020-12-01 |
노파르티스 아게 |
약제학적 병용물
|
|
SG11202009791VA
(en)
*
|
2018-04-09 |
2020-11-27 |
Origincell Therapeutics Co Ltd |
Anti-pd-l1 antibody and use thereof
|
|
WO2019200160A1
(en)
*
|
2018-04-11 |
2019-10-17 |
Tychan Pte. Ltd. |
Methods and compositions for treating yellow fever
|
|
CN112004558A
(zh)
*
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
|
CN119607195A
(zh)
*
|
2018-04-24 |
2025-03-14 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
|
|
CA3096993A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Medimmune Limited |
Formulations of human anti-pd-l1 antibodies
|
|
BR112020021855A2
(pt)
|
2018-04-27 |
2021-02-23 |
Biogen Ma Inc. |
anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
US11613571B2
(en)
*
|
2018-05-23 |
2023-03-28 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions comprising antibody variants
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
WO2019229296A1
(en)
*
|
2018-05-29 |
2019-12-05 |
Teknologian Tutkimuskeskus Vtt Oy |
Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
|
|
US20210206864A1
(en)
*
|
2018-05-31 |
2021-07-08 |
Ichnos Sciences SA |
Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
US20210253731A1
(en)
*
|
2018-06-14 |
2021-08-19 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis
|
|
CA3105071A1
(en)
*
|
2018-07-02 |
2020-01-09 |
Abcentra, Llc |
Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
MX2021000399A
(es)
*
|
2018-07-12 |
2021-05-27 |
F Star Therapeutics Ltd |
Moleculas de anticuerpo que se unen a cd137 y ox40.
|
|
AU2019301204B2
(en)
|
2018-07-12 |
2025-10-23 |
Invox Pharma Limited |
Antibody molecules that bind PD-L1 and CD137
|
|
CN110713537B
(zh)
*
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
|
WO2020024931A1
(en)
*
|
2018-07-31 |
2020-02-06 |
Shen Weiqun |
Anti-il-17a antibodies and use thereof
|
|
WO2020033646A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
EP3833693A4
(en)
*
|
2018-08-21 |
2023-06-07 |
ABL Bio Inc. |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
|
EP3846850A4
(en)
|
2018-09-06 |
2022-06-15 |
The Trustees of the University of Pennsylvania |
HUMANIZED ANTI-C5 ANTIBODIES AND USES THEREOF
|
|
CN111253485A
(zh)
*
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
|
MY206649A
(en)
*
|
2018-11-30 |
2024-12-30 |
I Mab Biopharma Us Ltd |
Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
|
|
EP3892300A4
(en)
*
|
2018-12-03 |
2022-12-14 |
Mabprotein Co.,Ltd. |
ANTIBODIES RECOGNIZING A NEO-EPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND ASSOCIATED APPLICATION
|
|
EP3893901A4
(en)
*
|
2018-12-11 |
2023-01-04 |
The Regents of the University of California |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES
|
|
TWI734279B
(zh)
*
|
2018-12-14 |
2021-07-21 |
美商美國禮來大藥廠 |
抗α-突觸核蛋白抗體及其用途
|
|
CN116063520A
(zh)
|
2019-01-30 |
2023-05-05 |
真和制药有限公司 |
抗gal3抗体及其用途
|
|
JP2022520106A
(ja)
*
|
2019-02-15 |
2022-03-28 |
ユニバーシティ オブ サザン カリフォルニア |
Ｌｙｍ－１およびｌｙｍ－２抗体組成物ならびに改善されたｃａｒ構築物
|
|
CN113661175A
(zh)
*
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
|
CA3129834A1
(en)
*
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
|
AU2020231366A1
(en)
|
2019-03-03 |
2021-08-12 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
EP3947445A1
(en)
*
|
2019-04-04 |
2022-02-09 |
Vanderbilt University |
Hiv/hcv cross-reactive antibodies and uses thereof
|
|
EP3958903A4
(en)
*
|
2019-04-24 |
2023-08-02 |
Janssen Biotech, Inc. |
ANTIBODY FORMULATION
|
|
CN113784985A
(zh)
*
|
2019-05-08 |
2021-12-10 |
诺华股份有限公司 |
T1dm和胰岛炎的治疗中使用的抗cd40抗体
|
|
TW202110878A
(zh)
*
|
2019-05-16 |
2021-03-16 |
法商賽諾菲公司 |
在神經系統中表現抗原結合蛋白
|
|
JP7407841B2
(ja)
*
|
2019-05-16 |
2024-01-04 |
斉魯制薬有限公司 |
クローディン１８ａ２に対する抗体及びその応用
|
|
CN113906052B
(zh)
*
|
2019-06-04 |
2024-02-13 |
普米斯生物技术(珠海)有限公司 |
一种抗ceacam5的单克隆抗体及其制备方法和用途
|
|
WO2020250204A1
(ko)
*
|
2019-06-13 |
2020-12-17 |
프레스티지 바이오파마 피티이. 엘티디. |
신규 cthrc1에 특이적 항체 및 이의 용도
|
|
FR3099160B1
(fr)
*
|
2019-07-23 |
2022-05-06 |
Univ Grenoble Alpes |
Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
|
|
MX2022001068A
(es)
*
|
2019-07-26 |
2022-02-14 |
Sinocelltech Ltd |
Anticuerpo anti-il17a humanizado y uso del mismo.
|
|
EP4003519A2
(en)
*
|
2019-07-31 |
2022-06-01 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
|
CN114929341A
(zh)
*
|
2019-08-16 |
2022-08-19 |
H.李.莫菲特癌症中心和研究所股份有限公司 |
用于治疗髓系恶性肿瘤的嵌合抗原受体
|
|
EP4034558A1
(en)
*
|
2019-09-26 |
2022-08-03 |
Roche Diagnostics GmbH |
Anti-csf-1r antibody
|
|
KR20220103095A
(ko)
*
|
2019-09-26 |
2022-07-21 |
우시 바이올로직스 아일랜드 리미티드 |
신규 항-pd-l1/항-lag-3 이중특이적 항체 및 그의 용도
|
|
EP4037699A1
(en)
*
|
2019-09-30 |
2022-08-10 |
SciRhom GmbH |
Protein binders to irhom2 epitopes
|
|
EP4041308A1
(en)
|
2019-10-07 |
2022-08-17 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
WO2021089559A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Medimmune Limited |
Anti il-33 therapeutic agent fpr treating renal disorders
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
US20220275103A1
(en)
*
|
2019-11-18 |
2022-09-01 |
CentricsBio, Inc. |
Anti-cd300c monoclonal antibody and biomarker thereof for preventing or treating cancer
|
|
US20230046834A1
(en)
*
|
2019-11-21 |
2023-02-16 |
Brown University |
Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells
|
|
MX2022007688A
(es)
*
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
JP2023510866A
(ja)
*
|
2020-01-13 |
2023-03-15 |
トゥルーバインディング，インコーポレイテッド |
抗ｇａｌ３抗体および使用方法
|
|
CN115190814A
(zh)
*
|
2020-01-24 |
2022-10-14 |
辉瑞公司 |
抗e-选择素抗体、组合物和使用方法
|
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
PE20221781A1
(es)
*
|
2020-02-07 |
2022-11-16 |
Agency Science Tech & Res |
Moleculas de union a antigeno contra alppl2 y/o alpp y usos de las mismas
|
|
JP7772702B2
(ja)
*
|
2020-02-10 |
2025-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｔｍｐｒｓｓ２抗体および抗原結合断片
|
|
JP2023514972A
(ja)
*
|
2020-02-12 |
2023-04-12 |
ザ スクリプス リサーチ インスティテュート |
長時間作用型ｇｍ－ｃｓｆおよび使用方法
|
|
WO2021162394A1
(ko)
*
|
2020-02-14 |
2021-08-19 |
충북대학교 산학협력단 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
GB202003632D0
(en)
*
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
WO2021045836A1
(en)
|
2020-04-02 |
2021-03-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
KR102485892B1
(ko)
*
|
2020-04-09 |
2023-01-09 |
주식회사 에이프릴바이오 |
고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
|
|
WO2021222168A2
(en)
*
|
2020-04-28 |
2021-11-04 |
Sola Biosciences Llc |
Compositions and methods for the treatment of tdp-43 proteinopathies
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CN116157151A
(zh)
|
2020-05-26 |
2023-05-23 |
真和制药有限公司 |
通过阻断半乳凝素-3治疗炎性疾病的方法
|
|
EP4157464A1
(en)
*
|
2020-05-26 |
2023-04-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
|
|
CN116323665A
(zh)
|
2020-05-29 |
2023-06-23 |
23和我公司 |
抗cd200r1抗体及其使用方法
|
|
WO2022012681A1
(en)
*
|
2020-07-16 |
2022-01-20 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric antigen receptors and uses thereof
|
|
EP4182022A1
(en)
|
2020-07-17 |
2023-05-24 |
Boehringer Ingelheim International GmbH |
Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
|
|
WO2022031576A1
(en)
*
|
2020-08-03 |
2022-02-10 |
Janssen Biotech, Inc. |
Materials and methods for multidirectional biotransportation in virotherapeutics
|
|
AU2021328262B2
(en)
*
|
2020-08-18 |
2025-06-26 |
Omeros Corporation |
Monoclonal antibodies, compositions and methods for detecting complement factor D
|
|
US12448449B2
(en)
*
|
2020-09-11 |
2025-10-21 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
PE20231573A1
(es)
*
|
2020-09-18 |
2023-10-04 |
Ichnos Sciences SA |
Anticuerpos biespecificos cd47-cd38
|
|
JP2023543152A
(ja)
*
|
2020-09-18 |
2023-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
|
|
US11795228B2
(en)
*
|
2020-09-30 |
2023-10-24 |
Dren Bio, Inc. |
Anti-CD94 antibodies and methods of use thereof
|
|
EP4236988A4
(en)
*
|
2020-10-30 |
2024-10-30 |
Rush University Medical Center |
INTRANASAL IMMUNOTHERAPY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
|
|
CN114456268B
(zh)
*
|
2020-11-09 |
2023-08-18 |
江苏中新医药有限公司 |
抗胞外-5’-核苷酸酶的抗体序列
|
|
CN114470189B
(zh)
*
|
2020-11-12 |
2024-01-16 |
达石药业(广东)有限公司 |
Ngf抗体在cipn性疼痛中的应用
|
|
IL303656A
(en)
*
|
2020-12-17 |
2023-08-01 |
Hoffmann La Roche |
Anti-hla-g antibodies and use thereof
|
|
CA3202629A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to npr1 agonists
|
|
WO2022129609A2
(en)
*
|
2020-12-18 |
2022-06-23 |
Ac Immune Sa |
Antibody delivery
|
|
KR20230142724A
(ko)
*
|
2021-01-08 |
2023-10-11 |
브리스톨-마이어스 스큅 컴퍼니 |
인자 XIa 억제제에 대한 항체 및 항원 결합 펩티드및 그의 용도
|
|
TW202302644A
(zh)
*
|
2021-03-04 |
2023-01-16 |
德商百靈佳殷格翰國際股份有限公司 |
治療gpp之方法
|
|
CN117157319A
(zh)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
结合cd3和cldn6的异二聚抗体
|
|
KR20230154311A
(ko)
*
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
WO2022195028A2
(en)
*
|
2021-03-18 |
2022-09-22 |
Medimmune Limited |
Therapeutic binding molecules
|
|
MX2023011267A
(es)
*
|
2021-03-24 |
2023-12-14 |
Janssen Biotech Inc |
Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
|
|
CR20230462A
(es)
*
|
2021-03-31 |
2023-11-30 |
Incyte Corp |
Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1 novedosos.
|
|
KR20230163503A
(ko)
*
|
2021-03-31 |
2023-11-30 |
메뤼스 엔.페. |
신규한 pd-1 결합 도메인
|
|
CN115260312B
(zh)
*
|
2021-04-30 |
2025-02-14 |
保诺科技（北京）有限公司 |
结合ox40的抗体或抗原结合片段
|
|
WO2022271884A2
(en)
*
|
2021-06-22 |
2022-12-29 |
Twist Bioscience Corporation |
Methods and compositions relating to covid antibody epitopes
|
|
US12448451B2
(en)
*
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
JP7472405B2
(ja)
*
|
2021-06-25 |
2024-04-22 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体
|
|
TWI864408B
(zh)
*
|
2021-06-25 |
2024-12-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
AU2022311906A1
(en)
*
|
2021-07-14 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
US11542340B1
(en)
*
|
2021-10-29 |
2023-01-03 |
Biodesix, Inc. |
Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
|
|
EP4626933A1
(en)
|
2022-11-30 |
2025-10-08 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
|
CN120513256A
(zh)
*
|
2023-01-20 |
2025-08-19 |
迈威(美国)生物治疗有限公司 |
抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
|
|
KR20250173600A
(ko)
|
2023-03-17 |
2025-12-10 |
옥시토프 파마 비.브이. |
항-포스포콜린 항체 및 그 사용 방법
|
|
WO2025257181A1
(en)
*
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|